TIL Quote, Financials, Valuation and Earnings

Bristol-Myers Squibb has a net margin of -- compared to Instil Bio's net margin of 21.93%. Instil Bio's return on equity of -- beat Bristol-Myers Squibb's return on equity of 32.01%.

Instil Bio has a consensus price target of $118.67, signalling upside risk potential of 464.54%. On the other hand Bristol-Myers Squibb has an analysts' consensus of $57.19 which suggests that it could grow by 22.06%. Given that Instil Bio has higher upside potential than Bristol-Myers Squibb, analysts believe Instil Bio is more attractive than Bristol-Myers Squibb.

Instil Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bristol-Myers Squibb has a beta of 0.392, suggesting its less volatile than the S&P 500 by 60.827%.

Instil Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol-Myers Squibb offers a yield of 5.21% to investors and pays a quarterly dividend of $0.62 per share. Instil Bio pays -- of its earnings as a dividend. Bristol-Myers Squibb pays out -54.35% of its earnings as a dividend.

Instil Bio quarterly revenues are --, which are smaller than Bristol-Myers Squibb quarterly revenues of $11.2B. Instil Bio's net income of -$28.2M is lower than Bristol-Myers Squibb's net income of $2.5B. Notably, Instil Bio's price-to-earnings ratio is -- while Bristol-Myers Squibb's PE ratio is 17.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Instil Bio is -- versus 2.00x for Bristol-Myers Squibb. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of -- compared to Instil Bio's net margin of 32.71%. Instil Bio's return on equity of -- beat Merck &'s return on equity of 39.02%.

Instil Bio has a consensus price target of $118.67, signalling upside risk potential of 464.54%. On the other hand Merck & has an analysts' consensus of $101.91 which suggests that it could grow by 31.36%. Given that Instil Bio has higher upside potential than Merck &, analysts believe Instil Bio is more attractive than Merck &.

Instil Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merck & has a beta of 0.429, suggesting its less volatile than the S&P 500 by 57.139%.

Instil Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 4.07% to investors and pays a quarterly dividend of $0.81 per share. Instil Bio pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Instil Bio quarterly revenues are --, which are smaller than Merck & quarterly revenues of $15.5B. Instil Bio's net income of -$28.2M is lower than Merck &'s net income of $5.1B. Notably, Instil Bio's price-to-earnings ratio is -- while Merck &'s PE ratio is 11.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Instil Bio is -- versus 3.08x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -- compared to Instil Bio's net margin of -907.48%. Instil Bio's return on equity of -- beat Moderna's return on equity of -29.23%.

Instil Bio has a consensus price target of $118.67, signalling upside risk potential of 464.54%. On the other hand Moderna has an analysts' consensus of $47.70 which suggests that it could grow by 81.63%. Given that Instil Bio has higher upside potential than Moderna, analysts believe Instil Bio is more attractive than Moderna.

Instil Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

Instil Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Instil Bio pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Instil Bio quarterly revenues are --, which are smaller than Moderna quarterly revenues of $107M. Instil Bio's net income of -$28.2M is higher than Moderna's net income of -$971M. Notably, Instil Bio's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Instil Bio is -- versus 3.25x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -- compared to Instil Bio's net margin of 26.7%. Instil Bio's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Instil Bio has a consensus price target of $118.67, signalling upside risk potential of 464.54%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $797.21 which suggests that it could grow by 35.5%. Given that Instil Bio has higher upside potential than Regeneron Pharmaceuticals, analysts believe Instil Bio is more attractive than Regeneron Pharmaceuticals.

Instil Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.331%.

Instil Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.3% to investors and pays a quarterly dividend of $0.88 per share. Instil Bio pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Instil Bio quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Instil Bio's net income of -$28.2M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Instil Bio's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 14.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Instil Bio is -- versus 4.77x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.